Ajanta Pharma Ltd. NSE: AJANTPHARM | BSE: 532331

Mid-range Performer

Download real time

2544.40 -5.20 (-0.20%)

25.78% Fall from 52W High

56,431

NSE+BSE Volume

NSE 16 Sep, 2025 1:49 PM (IST)

Ajanta Pharma Ltd. share price target

Ajanta Pharma Ltd. has an average share price target of 3022. The consensus estimate represents an upside of 18.77% from the last price of 2544.40. View 8 reports from 5 analysts offering long-term price targets for Ajanta Pharma Ltd..

Reco - This broker has downgraded this stock from it's previous report.
(eg. - Buy->Hold)

Target - Broker has maintained previous recommendation but reduced share price target.

Reco - This broker has upgraded this stock from it's previous report.
(eg. - Sell->Hold)

Target - Broker has maintained previous recommendation but increased share price target.

Load latest Google or static link led you to an intermediate page.

Click on any table column to sort reports by date, stock name, broker, price, target, upside or recommendation.

Summary	Date	Stock	Author	LTP	Target	Price at reco (Change since reco%)	Upside(%)	Type	Report		Discuss
	16 Sep 2025	Ajanta Pharma	Consensus Share Price Target	2544.40	3008.33	-	18.23	buy	pdf Detailed Estimates
	03 May 2024	Ajanta Pharma	ICICI Direct Target	2544.40	2875.00	2383.85 (6.73%)	Target met	Buy	pdf post cache		Broker Report Ajanta Pharma ICICI Direct pdf Copy Link Share on Share on Share on Share on Alert
	03 May 2024	Ajanta Pharma	BOB Capital Markets Ltd. Target	2544.40	2585.00	2383.85 (6.73%)	Target met	Buy	pdf post cache		Broker Report Ajanta Pharma (BUY): Strong margins; growth momentum to continue BOB Capital Markets Ltd. Strong quarter with EBITDA/PAT beat of 8% each, led by reduction in API prices, logistics costs and reduced intensity of US price erosion pdf Copy Link Share on Share on Share on Share on Alert
	02 May 2024	Ajanta Pharma	Motilal Oswal Target	2544.40	2565.00	2234.00 (13.89%)	Target met	Buy	pdf post cache		Broker Report Higher opex leads to EBITDA/PAT miss Motilal Oswal Ajanta Pharma (AJP) delivered in-line sales in 4QFY24. However, EBITDA/PAT came in lower than our expectations, due to higher opex and higher tax outgo. AJP continued to outperform the industry in domestic formulation (DF) and Asia market. The performance is expected to improve in the Africa branded generics market going forward. pdf Copy Link Share on Share on Share on Share on Alert
	31 Oct 2023	Ajanta Pharma	BOB Capital Markets Ltd. Target	2544.40	2070.00	1763.20 (44.31%)	Target met	Buy	pdf post cache		Broker Report Ajanta Pharma (BUY): Buoyant margins but higher tax weighs on PAT BOB Capital Markets Ltd. Strong Q2 gross/EBITDA margins at 75%/28% drove a 7% EBITDA beat, though higher tax pulled PAT 2% below consensus pdf Copy Link Share on Share on Share on Share on Alert
	29 Jul 2023	Ajanta Pharma	ICICI Securities Limited	2544.40	1870.00	1615.75 (57.47%)	Target met	Buy	pdf post cache		Broker Report Margin improvement story unfolding ICICI Securities Limited Ajanta Pharma’s Q1FY24 result surprised positively on margin front. Softening of raw material and freight costs have started showing improvement in gross (+482bps YoY) and EBITDA (+325bps) margins. Traction in India branded business continues to be robust, with 14% growth vs market growth rate of 9%, while momentum in export branded business is expected to gain in quarters ahead. pdf Copy Link Share on Share on Share on Share on Alert
	28 Jul 2023	Ajanta Pharma	BOB Capital Markets Ltd. Target	2544.40	1860.00	1615.75 (57.47%)	Target met	Buy	pdf post cache		Broker Report Ajanta Pharma (BUY): Q1 beat sparked by sharp margin recovery BOB Capital Markets Ltd. Strong Q1 beat with EBITDA/PAT of Rs 2.7bn/Rs 2.1bn coming in 17%/ 39% ahead of consensus due to margin recovery pdf Copy Link Share on Share on Share on Share on Alert
	28 Jul 2023	Ajanta Pharma	ICICI Direct Target	2544.40	1950.00	1615.75 (57.47%)	Target met	Buy	pdf post cache		Broker Report Ajanta Pharma ICICI Direct pdf Copy Link Share on Share on Share on Share on Alert
	06 May 2023	Ajanta Pharma	Motilal Oswal Target	2544.40	1490.00	1298.45 (95.96%)	Target met	Buy	pdf post cache		Broker Report Disruption in Africa segment/higher opex drags earnings Motilal Oswal pdf Copy Link Share on Share on Share on Share on Alert
	06 May 2023	Ajanta Pharma	BOB Capital Markets Ltd. Reco Target	2544.40	1520.00	1298.45 (95.96%)	Target met	Buy	pdf post cache		Broker Report Ajanta Pharma (BUY): Margins appear to have bottomed out; raise to BUY BOB Capital Markets Ltd. Strong India and US growth in Q4 (17% YoY each) offset by declines in other businesses pdf Copy Link Share on Share on Share on Share on Alert
	06 May 2023	Ajanta Pharma	ICICI Direct Target	2544.40	1520.00	1298.45 (95.96%)	Target met	Buy	pdf post cache		Broker Report Ajanta Pharmaceuticals ICICI Direct pdf Copy Link Share on Share on Share on Share on Alert
	10 Mar 2023	Ajanta Pharma	Motilal Oswal Target	2544.40	1410.00	1219.90 (108.57%)	Target met	Buy	pdf post cache		Broker Report Healthy Work-in-progress on reducing cost pressure to boost outlook Motilal Oswal pdf Copy Link Share on Share on Share on Share on Alert
	02 Feb 2023	Ajanta Pharma	ICICI Direct Target	2544.40	1385.00	1191.50 (113.55%)	Target met	Buy	pdf post cache		Broker Report Ajanta Pharmaceuticals ICICI Direct pdf Copy Link Share on Share on Share on Share on Alert
	04 Nov 2022	Ajanta Pharma	ICICI Direct Target	2544.40	1505.00	1256.20 (102.55%)	Target met	Buy	pdf post cache		Broker Report Ajanta Pharmaceuticals ICICI Direct pdf Copy Link Share on Share on Share on Share on Alert
	04 Nov 2022	Ajanta Pharma	BOB Capital Markets Ltd.	2544.40	1470.00	1256.20 (102.55%)	Target met	Hold	pdf post cache		Broker Report Ajanta Pharma (HOLD): No respite from margin pressure; cut to HOLD BOB Capital Markets Ltd. Q2 revenue growth muted at 6% YoY as lower Africa/US sales offset a strong uptick in India/Asia business pdf Copy Link Share on Share on Share on Share on Alert
	04 Nov 2022	Ajanta Pharma	Motilal Oswal	2544.40	1560.00	1256.20 (102.55%)	Target met	Buy	pdf post cache		Broker Report India and Asia drives, while the US and Africa drag earnings Motilal Oswal pdf Copy Link Share on Share on Share on Share on Alert
	29 Jul 2022	Ajanta Pharma	ICICI Direct	2544.40	1495.00	1278.60 (99.00%)	Target met	Buy	pdf post cache		Broker Report Ajanta Pharmaceuticals ICICI Direct pdf Copy Link Share on Share on Share on Share on Alert
	22 Jun 2022	Ajanta Pharma	ICICI Direct	2544.40	1305.00	1214.80 (109.45%)	Pre-Bonus/ Split	Hold	pdf post cache		Broker Report Ajanta Pharmaceuticals ICICI Direct pdf Copy Link Share on Share on Share on Share on Alert
	11 May 2022	Ajanta Pharma	BOB Capital Markets Ltd. Target	2544.40	2050.00	1684.70 (51.03%)	Pre-Bonus/ Split	Buy	pdf post cache		Broker Report Ajanta Pharma (BUY): Margin stress continues BOB Capital Markets Ltd. Q4 revenue 6% ahead of our estimate but margins disappointed with gross/EBITDA margin contraction of 530bps/1050bps YoY to ~72%/24% pdf Copy Link Share on Share on Share on Share on Alert
	11 May 2022	Ajanta Pharma	ICICI Direct	2544.40	1955.00	1684.70 (51.03%)	Pre-Bonus/ Split	Buy	pdf post cache		Broker Report Ajanta Pharmaceuticals ICICI Direct pdf Copy Link Share on Share on Share on Share on Alert
	22 Mar 2022	Ajanta Pharma	Motilal Oswal Target	2544.40	2500.00	1953.80 (30.23%)	Pre-Bonus/ Split	Buy	pdf post cache		Broker Report Robust outlook in the Branded Generics segment Motilal Oswal AJP delivered 13% sales CAGR from Dec'18 to Dec'21, led by steady traction in existing therapies and ramp-up in newly added therapies and the Trade Generics segment. It delivered a sales growth of 23% YoY to INR7.3b (30% of sales) in 9MFY22. With the easing of COVID-19 cases, doctor-patient connectivity has significantly improved, particularly in the Ophthalmology/Dermatology segment (39% of DF sales in 9MFY22). This bodes well for better growth prospects for AJP. This, along with enhanced marketing efforts in the Cardiology segment (~41% of DF sales in 9MFY22)... pdf Copy Link Share on Share on Share on Share on Alert
more loading

* Please note that subscribers can download a maximum of 300 reports a month and 70 reports everyday.

Advisor Screeners